98 related articles for article (PubMed ID: 7744655)
1. Comments on use of mitotane.
Watson AD
J Am Vet Med Assoc; 1995 Jan; 206(1):25. PubMed ID: 7744655
[No Abstract] [Full Text] [Related]
2. Hair chewing associated with suspected hyperadrenocorticism in a dog.
Chastain CB
J Am Vet Med Assoc; 1978 Mar; 172(5):573-4. PubMed ID: 632195
[TBL] [Abstract][Full Text] [Related]
3. Hyperadrenocorticism: treating dogs.
Brown CG; Graves TK
Compend Contin Educ Vet; 2007 Mar; 29(3):132-4, 136, 138 passim; quiz 144-5. PubMed ID: 17726933
[TBL] [Abstract][Full Text] [Related]
4. A case of adrenal gland dependent hyperadrenocorticism with mitotane therapy in a Yorkshire terrier dog.
Lee YM; Kang BT; Jung DI; Park C; Kim HJ; Kim JW; Lim CY; Park EH; Park HM
J Vet Sci; 2005 Dec; 6(4):363-6. PubMed ID: 16294004
[TBL] [Abstract][Full Text] [Related]
5. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism.
Clemente M; De Andrés PJ; Arenas C; Melián C; Morales M; Pérez-Alenza MD
Vet Rec; 2007 Dec; 161(24):805-9. PubMed ID: 18083978
[TBL] [Abstract][Full Text] [Related]
6. Use of urine cortisol:creatinine ratio versus adrenocorticotropic hormone stimulation testing for monitoring mitotane treatment of pituitary-dependent hyperadrenocorticism in dogs.
Angles JM; Feldman EC; Nelson RW; Feldman MS
J Am Vet Med Assoc; 1997 Oct; 211(8):1002-4. PubMed ID: 9343543
[TBL] [Abstract][Full Text] [Related]
7. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
Reine NJ
Clin Tech Small Anim Pract; 2007 Feb; 22(1):18-25. PubMed ID: 17542193
[TBL] [Abstract][Full Text] [Related]
8. Problems associated with medical therapy of canine hyperadrenocorticism.
Nichols R
Probl Vet Med; 1990 Dec; 2(4):551-6. PubMed ID: 2134073
[TBL] [Abstract][Full Text] [Related]
9. Medical treatment of hyperadrenocorticism in the dog.
Braddock JA
Aust Vet J; 2003; 81(1-2):31-3. PubMed ID: 15084005
[No Abstract] [Full Text] [Related]
10. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms.
Kintzer PP; Peterson ME
J Am Vet Med Assoc; 1994 Jul; 205(1):54-61. PubMed ID: 7928549
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of urine protein content in dogs with pituitary-dependent hyperadrenocorticism.
Hurley KJ; Vaden SL
J Am Vet Med Assoc; 1998 Feb; 212(3):369-73. PubMed ID: 9470045
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism.
Barker EN; Campbell S; Tebb AJ; Neiger R; Herrtage ME; Reid SW; Ramsey IK
J Vet Intern Med; 2005; 19(6):810-5. PubMed ID: 16355673
[TBL] [Abstract][Full Text] [Related]
13. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
Randolph JF; Toomey J; Center SA; Scarlett JM; Reimers T; Graham P; Nachreiner RF
Am J Vet Res; 1998 Mar; 59(3):258-61. PubMed ID: 9522940
[TBL] [Abstract][Full Text] [Related]
14. Old or new? A comparison of mitotane and trilostane for the management of hyperadrenocorticism.
Griffies JD
Compend Contin Educ Vet; 2013 May; 35(5):E3. PubMed ID: 23677783
[TBL] [Abstract][Full Text] [Related]
15. Perianal adenomas and hypertestosteronemia in a spayed bitch with pituitary-dependent hyperadrenocorticism.
Dow SW; Olson PN; Rosychuk RA; Withrow SJ
J Am Vet Med Assoc; 1988 May; 192(10):1439-41. PubMed ID: 2839445
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane.
Peterson ME; Kintzer PP
Vet Clin North Am Small Anim Pract; 1997 Mar; 27(2):255-72. PubMed ID: 9076906
[TBL] [Abstract][Full Text] [Related]
17. Acute hepatopathy associated with mitotane administration in a dog.
Webb CB; Twedt DC
J Am Anim Hosp Assoc; 2006; 42(4):298-301. PubMed ID: 16822769
[TBL] [Abstract][Full Text] [Related]
18. Mitotane (o,p'-DDD) resistance in a dog with pituitary-dependent hyperadrenocorticism and phaeochromocytoma.
Bennett PF; Norman EJ
Aust Vet J; 1998 Feb; 76(2):101-3. PubMed ID: 9578778
[TBL] [Abstract][Full Text] [Related]
19. [Formal pathogenesis, average age and breed distribution in the comparison of 61 Lysodren-treated and 36 untreated cases of canine hyperadrenocorticism which were dissected in the years 1975 to 1991 at the Institute for Veterinary Pathology of the Free University of Berlin].
Nothelfer HB; Weinhold K
Berl Munch Tierarztl Wochenschr; 1992 Sep; 105(9):305-11. PubMed ID: 1417721
[TBL] [Abstract][Full Text] [Related]
20. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane.
Helm JR; McLauchlan G; Boden LA; Frowde PE; Collings AJ; Tebb AJ; Elwood CM; Herrtage ME; Parkin TD; Ramsey IK
J Vet Intern Med; 2011; 25(2):251-60. PubMed ID: 21352377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
